Semaglutide size: what the pen, dose and pack formats actually mean

Why the dose ladder is built the way it is

The titration schedule for Wegovy (starting low, stepping up gradually) follows directly from the STEP 1 trial, a 68-week study published in the New England Journal of Medicine that established 2.4 mg weekly as the maintenance dose producing roughly 15% average body-weight reduction. Researchers tested a slow-step escalation because semaglutide slows gastric emptying and the gastrointestinal system needs time to adjust. The 0.25 mg starting dose was not chosen to produce weight loss. It exists to settle tolerance. From there, doses increase roughly every four weeks: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and then 2.4 mg. That five-rung ladder is calibrated to the biology of GI adaptation, not to a convenient number.

One misconception is worth putting to rest gently: some people assume a higher dose always means better results. In practice, the maintenance dose is the target, the intermediate sizes are transitional, and the prescriber decides both the pace and the ceiling based on how a patient is tolerating treatment. Skipping steps is not how the licensed schedule works. The NHS semaglutide medicines page sets this out clearly.

The 7.2 mg dose, approved by the MHRA in January 2026 and expanded in April 2026 to a dedicated single-dose pen, adds a further option for adults with a BMI of 30 or above. Trials at that strength reported around 20.7% average weight loss over 72 weeks, approaching the results seen with tirzepatide at its top dose. Titration still starts from 0.25 mg; 7.2 mg is reached only after a prescriber has reviewed progress at each preceding step.

Pen size, dose size and pack size: three different things

It is easy to conflate these, and worth keeping them distinct. The dose size is the amount of medicine in micrograms or milligrams delivered by one injection. The pen size refers to the physical device, Wegovy pens are auto-injectors with a built-in covered needle; the 7.2 mg single-dose pen has a slightly different auto-dosing mechanism that locks after use. The pack size is the number of pens per carton, which is standardised at four for the injection (one month's supply). These distinctions matter if you are reading a prescription or comparing what different cartons cover.

For more detail on the physical dimensions of the pen itself, the Wegovy pen size guide covers the specifics. If you have questions about the needle gauge used with the device, semaglutide syringe and needle sizing goes into that separately. And if you are thinking about how pack formats affect ordering, Wegovy pack size explains exactly what a standard carton contains.

Oral semaglutide: a different size, a different format entirely

The Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management, follows its own entirely separate dose ladder: 1.5 mg, 4 mg, 9 mg, and then 25 mg as the maintenance dose, taken once daily. These numbers are not interchangeable with the injection strengths, a 9 mg tablet is not equivalent to a 0.9 mg injection. The bioavailability of oral semaglutide, delivered with an absorption enhancer called SNAC, is quite different from subcutaneous absorption, which is why the tablet doses look larger on paper.

The OASIS 4 phase-3 trial found around 13.6% average weight loss at 64 weeks versus placebo alongside lifestyle changes, with roughly 17% among participants who stayed fully adherent throughout. Storage is straightforward: no refrigeration needed, which makes it an option worth exploring for people who travel regularly or simply find the idea of injections uncomfortable. You can read more about the full treatment picture on the semaglutide overview page or Wegovy in the UK for context on both formats side by side.

It is worth knowing that Rybelsus (also oral semaglutide) uses 3 mg, 7 mg and 14 mg tablets. Those are licensed for type 2 diabetes, not weight management. The Wegovy tablet doses (1.5 mg through to 25 mg) are entirely distinct and must not be confused with Rybelsus steps.

What semaglutide size means in practice when you start treatment

A prescriber working through a structured weight-management service will consider several things before settling on a starting point: your current weight, any relevant health conditions, medicines you already take, and how you have responded to weight-loss treatment before. The licensed schedule sets the framework; the prescriber works within it. The consultation page outlines how the process works at nume, where a GPhC-registered Independent Prescriber reviews your case personally, the same day.

Side effects are most common at dose increases, nausea, loose stools, and indigestion tend to peak in the days after stepping up and settle as your body adjusts. If you are concerned about how semaglutide might make you feel at higher doses, flu-like symptoms and Wegovy is worth reading before you start. For anyone still weighing up whether the injection or tablet route makes more sense, the weight-loss treatment options page sets out the broader picture. Our clinical team's background is on the prescriber profile page if you would like to know more before booking.